Anthelios Sx is a drug owned by Loreal Usa Products Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 24, 2013. Details of Anthelios Sx's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5587150 | Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate |
Dec, 2013
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Anthelios Sx is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Anthelios Sx's family patents as well as insights into ongoing legal events on those patents.
Anthelios Sx's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Anthelios Sx's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 24, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Anthelios Sx Generics:
There are no approved generic versions for Anthelios Sx as of now.
About Anthelios Sx
Anthelios Sx is a drug owned by Loreal Usa Products Inc. It is used for protecting the skin from harmful UV rays and reducing the risk of sunburn and skin damage. Anthelios Sx uses Avobenzone; Ecamsule; Octocrylene as an active ingredient. Anthelios Sx was launched by Loreal Usa in 2006.
Approval Date:
Anthelios Sx was approved by FDA for market use on 21 July, 2006.
Active Ingredient:
Anthelios Sx uses Avobenzone; Ecamsule; Octocrylene as the active ingredient. Check out other Drugs and Companies using Avobenzone; Ecamsule; Octocrylene ingredient
Treatment:
Anthelios Sx is used for protecting the skin from harmful UV rays and reducing the risk of sunburn and skin damage.
Dosage:
Anthelios Sx is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2%;2%;10% | CREAM | Over the counter | TOPICAL |